SecBot SecBot
8-K ·Filed Nov 12, 2026

SLS

SELLAS Life Sciences Group, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed5d ago SEC0001390478-26-000021
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Phase 3 REGAL topline readout this month is the primary binary catalyst. Positive results would validate GPS as a potential AML therapy and could trigger a BLA filing. Negative results would remove the company's lead pipeline asset.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

SLS drug pipeline →

galinpepimut-S

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
Next catalyst
None dated

What to watchWatch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$7.86
T+0 close · Nov 12, 2026 · via day close
Latest settled
−4.96%
T+1 · $7.47
Vs SPY
−3.05%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $7.86entry
  2. T+1 · yesterday −4.96%α −3.05% · $7.47
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SELLAS reported Q3 2026 net loss of $10.1M ($0.05 per share), in line with the $-0.05 consensus. Cash and equivalents stood at $134.7M. The key catalyst is the upcoming topline readout of the Phase 3 REGAL trial of GPS in AML, expected this month, and preliminary Phase 2 SLS009 data expected in Q4 2026.

Key Financial Metrics

EPS
−$0.05
est −$0.05 · 0.0%
Rating
in line

Key Facts

  • Q3 2026 net loss of $10.1M, or $0.05 per share, vs $6.8M loss ($0.06) in Q3 2025
  • Cash and cash equivalents of $134.7M as of September 30, 2026
  • 80th event in Phase 3 REGAL trial of GPS occurred in October 2026; topline results expected this month
  • 40 of 80 patients enrolled in Phase 2 trial of SLS009 in newly diagnosed AML; preliminary topline data expected Q4 2026
  • Phase 2 data for SLS009 in relapsed/refractory AML to be presented at ASH December 2026

Financial Impact

Net loss widened to $10.1M from $6.8M in Q3 2025; R&D spend increased to $7.0M from $4.2M; cash position $134.7M

net losscashR&D expenses

Risk Factors

  • Phase 3 REGAL trial may fail to meet its primary endpoint, eliminating the lead program
  • Phase 2 SLS009 data may disappoint, reducing pipeline optionality
  • Cash burn rate increased to $10.1M per quarter; $134.7M provides runway but no revenue stream

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001390478-26-000021
Document: sls-20261112.htm0001390478-26-000021
Document: 0001390478-26-000021-index-headers.html0001390478-26-000021
Document: 0001390478-26-000021-index.html0001390478-26-000021
Document: 0001390478-26-000021.txt0001390478-26-000021
8-K Data (Synthetic)0001390478-26-000021

Track record

16 reports on SLS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today 424B5 Bearish 6/10 Entry $16.40 Now $19.15 −16.74% settles Feb 17
  2. Nov 17, 2026today Press Release Bearish 6/10 Entry $18.59 Now $19.15 −3.01% settles Feb 17
  3. Nov 17, 2026today 8-K Bullish 7/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
  4. Nov 17, 2026today Press Release Bullish 8/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
  5. Nov 12, 20265d ago 8-K Neutral 5/10 Viewing Entry $7.86 Now $19.15 +143.64% settles Feb 11
  6. Nov 10, 20267d ago SC 13G Neutral 3/10 Entry $8.37 Now $19.15 +128.79% settles Feb 8
  7. Nov 3, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.87 Now $19.15 +115.90% settles Feb 1
  8. Oct 28, 202620d ago Press Release Mixed 7/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
  9. Oct 27, 202621d ago SC 13G/A Neutral 3/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
  10. Sep 25, 20267w ago Press Release Neutral 3/10 Entry $11.61 Now $19.15 +64.94% settles Dec 21
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (16h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026